Thursday, May 26, 2022 7:43:46 PM
6:46 pm ET May 26, 2022 (Dow Jones) Print
By Stephen Nakrosis
Shares of PMV Pharmaceuticals Inc. were trading higher in Thursday's after-hours market, following the company's announcement that it would be presenting data from its lead program, PC14586, at the 2022 American Society of Clinical Oncology meeting next month.
PMV said its abstract describes "preliminary outcomes from 29 patients, including 21 efficacy evaluable, from the ongoing Phase 1/2 PYNNACLE trial of PC14586 in patients with advanced solid tumors that have a p53 Y220C mutation." PMV said the preliminary results "represent the first clinical evidence of targeting a p53 Y220C mutation."
At 6:37 p.m. ET, PMV's shares were trading 17.79% higher at $15.56 a share. Volume at the time topped 2.1 million shares. The company's stock finished the day with a 0.92% gain, closing at $13.21 a share.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
PMVP
New York Yankees and Duke Basketball
Recent PMVP News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 12:00:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:14 PM
- PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights • GlobeNewswire Inc. • 05/09/2024 12:00:00 PM
- PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors • GlobeNewswire Inc. • 03/27/2024 12:00:00 PM
- PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s Cancer • GlobeNewswire Inc. • 03/18/2024 08:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 09:05:19 PM
- PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights • GlobeNewswire Inc. • 02/29/2024 09:01:00 PM
- PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/26/2024 01:00:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/24/2024 02:01:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/22/2024 09:06:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/22/2024 09:04:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/18/2024 09:02:53 PM
- PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway • GlobeNewswire Inc. • 01/18/2024 09:01:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/11/2024 09:18:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 09:01:59 PM
- PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development • GlobeNewswire Inc. • 01/05/2024 09:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 01:00:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 01:00:42 PM
- PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights • GlobeNewswire Inc. • 11/09/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/12/2023 09:02:32 PM
- PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C Mutation • GlobeNewswire Inc. • 10/12/2023 04:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/11/2023 08:02:52 PM
- PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Host a KOL Webinar • GlobeNewswire Inc. • 10/11/2023 04:00:00 PM
- PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics • GlobeNewswire Inc. • 09/20/2023 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/18/2023 08:26:37 PM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM